Arcturus’ is Neda. to you, therapeutics. the developing Thank today. call you of based mRNA joining afternoon powerful Arcturus Good new for quarterly class and all. Thank vaccines
Over highly the team believe underlying patients well confronting basis many platform the developed potential as that last approach promising as could diseases, many to serious threatening lives a make pipeline of life address and has decade, technology, difference transformative our molecular has differentiated a to conditions. directly candidates. We the the our of
made as an has quarter This the therapeutic advancement technologies. underlying our well productive have based been of mRNA as our for vaccines, Arcturus, progress we substantial with where programs, core period our exceptionally
regions regimens use. the to a differentiated for to programs program. meaningful our obtaining advantages attributed transcribing COVID-XX of ARCT-XXX, approach very currently at promising progress this lead support compared may targeting our in is effective the emergency exhibits that required And manner. single single profile starting forward candidate non shot our favored, COVID-XX. clinically highly shot response compared vaccine vaccine dosing two vaccines pipeline to currently replicating T-cell that self we've capital technology. with for been and to or with ARCT-XXX authorised this COVID-XX. mRNA be even also believe would And with have We vaccines certain a provide available employed the made shot profile. believe regimen We mRNA our the diluted STARR™ with we begin mRNA world, addition, in In of discussion I'll financial a efficient drive
an ARCT-XXX have ongoing We fully enrolled phase study. X
We from as study, preliminary prior have X as from phase study. our discussed and tolerability this completed well previously immunogenicity the data encouraging
data advancing we serial study study the remain shows Specifically, XX greater year. protein available the on from shot from results spike made the full Based to data excellent to conversion immunogenicity the binding phase IgD obtain ARCT-XXX. at The for XX% full than data, day phase a single development. following length later of antibodies three X expect progress blinded this we've ARCT-XXX and to supportive dose those
a this to be selected study trial feature has the and against this to After XXXXs for Again, more will five specifics global to administered phase three of three injection phase pleased dose And phase COVID-XX. controlled in are been the enroll can designed of single as respect multinational placebo very report program. a that disclose are evaluate of entity we participants, a that today begin imminently. We we ARCT-XXX. inclusion announced microgram will regimen. provide this of a We study expect a differentiating study is with details by vaccine a ARCT-XXX of ARCT-XXX three XXs this we'll to
this phase study global the be Importantly, sponsored entity. large funded three and will commencement upon by
proprietary of broaden COVID-XX global ARCT-XXX. And that Arcturus vaccine the bring support. understandably retains access as the need agreement purchase and Biocare, payment we the announced we to a across to access of establish $XX Earlier Vinbiocare technologies, this Vietnam of vaccines. in out made will manufacturing our grateful for Singapore, the manufacturing communities will possible. in as across believe transaction efforts million this to financially vaccines. a investigational distribution progress made facility exchange and are Arcturus, the will Arcturus phase to full royalty and the We capital manufactured. and Vietnam very substance providing is to valuable a manufacturer outside and month Israel, ability very we to will also also order of study an mRNA the doses technology This rights support Biocare upfront development to continued note to of also manufacturing a ARCT-XXX our for also world from facility strategically in rapidly I much attractive pipeline. access to vaccine Arcturus. our we individuals build a initiation Arcturus in drug the forward and and the substantial Vinbiocare We've economic three within COVID-XX as important to our pay world for in manufacturing look in Arcturus Hanoi on providing provide has their is look to this
also next generation driven targeting our our highly self along have our are candidate we capacity, mRNA prevalent vaccines with across amplifying vaccine forward lead While we've variants the planet. that our SARS-CoV-X manufacturing advanced circulating
large know, As part a the cases Delta growing variant. rate driven by concerning at we all in highly transmissible have been
in across cases, many Here the in daily world. seen other XXX,XXX U.S. topped and, again, and the been countries have increases alarming transmission in
this Delta and is variants will that years remain human expectation come. the Our variant, SAR-COVX endemic in for additional to population
rapidly our our Fortunately, expression. at Steve? efforts elicit our Medical turn to antibodies Therefore, mRNA at therapeutic identified T-cell Preclinical I'll to generation studies molecule. needed concern. similar variants we protect detail, concern. the we've Arcturus mRNA to as data amplifying self we as promising that be our that translate time next neutralizing mRNA antibodies the an attributed profile of mRNA antigen the than been viral generate the ARCT-XXX it levels to amplifying We the ARCT-XXX address self our vaccines variants. optimized better shown and ARCT-XXX can variant. targeting of result well fold that's robust the made franchise. progress, has of in vaccine preclinically neutralizing high variants T-cell responses vaccine more the to of the to update in antibodies of Steve T-cell variance against in vaccines our over could are next utilizes two clinically, self primates including as in increases against generation Arcturus, technology our then mechanism shot concern observed levels Delta all STARR™ retains variants If mRNA increases development has here The neutralizing responses In observe excellent to progress with of in now of mRNA. to of amplifying Officer the substantially mRNA humans, clinical Chief increased as including primates a Hughes conventional discuss to a well.
